AI News NQ Analysis

台灣首見變種M痘境外移入 疾管署籲有風險者快打滿疫苗

NQ 評分 95/100

AI 摘要(NQ 加工版)

疾管署公布新增2例M痘病例,其中1例自泰國移入的病例,經基因分型鑑定確認為台灣首見的M痘病毒第I分支Ib亞型。疾管署呼籲符合公費疫苗資格的風險族群,應盡速完成兩劑疫苗接種。

AI 分析

常見問題

Q: What new Mpox development was announced in Taiwan?
A: Taiwan announced its first detected case of the Mpox clade I Ib substrain, a new variant for the country, found in a person who had traveled to Thailand.
Q: How many new Mpox cases were reported in May?
A: Two new cases were reported in May: one domestic case and one imported case from Thailand.
Q: What is the significance of this new imported case?
A: It is the first time the clade I Ib virus strain has been identified in Taiwan since Mpox became a notifiable infectious disease in 2022; all previous cases were of the clade II strain.
Q: What is the Taiwan CDC's primary recommendation?
A: The CDC strongly advises all eligible individuals, especially those with high-risk behaviors, to complete the two-dose Mpox vaccination course as soon as possible.
Q: How effective is the Mpox vaccine according to the article?
A: A complete two-dose vaccination provides about 90% protection against the Mpox virus, while a single dose offers only 40% to 80% protection. The vaccine is effective against both clade I and clade II strains.